Celcuity (CELC) Expected to Announce Earnings on Wednesday

Celcuity (NASDAQ:CELC) will likely be posting its Q3 2025 results after the market closes on Wednesday, November 12th. Analysts expect the company to announce earnings of ($1.05) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.14). On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celcuity Trading Up 0.4%

NASDAQ:CELC opened at $74.52 on Monday. The firm has a 50-day simple moving average of $58.60 and a 200-day simple moving average of $34.56. Celcuity has a one year low of $7.57 and a one year high of $83.00. The firm has a market cap of $3.16 billion, a P/E ratio of -21.60 and a beta of 0.72. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CELC shares. Guggenheim began coverage on shares of Celcuity in a research note on Monday, September 22nd. They issued a “buy” rating for the company. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. Leerink Partners boosted their price target on Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, July 28th. Needham & Company LLC set a $95.00 price objective on Celcuity in a research report on Monday, October 20th. Finally, HC Wainwright boosted their target price on shares of Celcuity from $66.00 to $77.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and an average target price of $65.50.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CELC. Soleus Capital Management L.P. raised its stake in Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after buying an additional 437,696 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Celcuity by 27.6% during the second quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock valued at $10,263,000 after acquiring an additional 166,324 shares in the last quarter. Captrust Financial Advisors increased its holdings in shares of Celcuity by 2.3% during the second quarter. Captrust Financial Advisors now owns 570,441 shares of the company’s stock valued at $7,615,000 after acquiring an additional 12,838 shares in the last quarter. Bank of America Corp DE raised its position in shares of Celcuity by 4.4% in the 2nd quarter. Bank of America Corp DE now owns 262,874 shares of the company’s stock valued at $3,509,000 after purchasing an additional 11,145 shares during the last quarter. Finally, Quantinno Capital Management LP raised its position in shares of Celcuity by 20.7% in the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after purchasing an additional 41,756 shares during the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.